Press Releases for CVTX

Press Releases
Gilead Sciences Completes Acquisition of CV Therapeutics
AnalystChoice.Com Free Investment Opinion on PPDI, MEDX, CVTX and OSIP
Zacks Analyst Blog Highlights: Analog Devices Inc., Gilead Sciences, CV Therapeutics, Koninklijke Philips Electronics N.V., And Skyworks Solutions, Inc.
CV Therapeutics' Board of Directors Recommends Stockholders Accept Gilead Sciences' $20.00 per Share Cash Tender Offer
Run of 100% Profitable Stock Alerts Marches on for BullTrade
CV Therapeutics Announces Presentations at the American College of Cardiology 58th Annual Scientific Session
Astellas to Terminate Offer for CV Therapeutics - Mar 16 2009 3:19AM
Zacks Industry Outlook Highlights: Roche, Genentech, Gilead Sciences and CV Therapeutics
Zacks Analyst Blog Highlights: Gilead Sciences, CV Therapeutics, The Boeing Co, Northrop Grumman Corp and eBay Inc.
CV Therapeutics' Board of Directors Rejects Astellas' Tender Offer
Gilead Sciences Agrees to Acquire CV Therapeutics for $20.00 Per Share
Astellas to Nominate Two Directors and Submit Proposal to Remove Remaining Four Directors of CV Therapeutics - Mar 6 2009 11:52PM
Astellas to Nominate Two Directors and Submit Proposal to Remove Remaining Four Directors of CV Therapeutics - Mar 6 2009 8:15AM
CV Therapeutics Reports Phase 1 Data Showing Proof of Concept for CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
Ranexa(R) Now Available in United Kingdom and Germany
Astellas Commences Tender Offer to Acquire All Outstanding Shares of CV Therapeutics for $16.00 Per Share in Cash - Feb 27 2009 11:52PM
CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas' Tender Offer
Astellas Files Lawsuit against CV Therapeutics
Astellas Commences Tender Offer to Acquire All Outstanding Shares of CV Therapeutics for $16.00 Per Share in Cash - Feb 27 2009 4:23AM
Zacks Analyst Blog Highlights: Brasil Telecom ParticipaÃ§ÃµEs S.A., Tele Norte Leste ParticipaÃ§ÃµEs SA, CV Therapeutics Inc., Allegheny Energy, Inc. And Citigroup Inc.
Zacks Analyst Blog Highlights: Brasil Telecom Participacoes S.A., Tele Norte Leste Participacoes SA, CV Therapeutics Inc., Allegheny Energy, Inc. And Citigroup Inc.
Astellas Pharma Issues Statement Regarding CV Therapeutics Rejection of All-Cash Proposal
CV Therapeutics' Board of Directors Rejects Astellas Unsolicited Proposal
CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results
CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350 - Feb 11 2009 4:13PM
Wall Street News Alert: Breaking Investors Alert for Wednesday: SOIS! January 28, 2009
CV Therapeutics Statement on Unsolicited Proposal From Astellas
Astellas Proposes to Acquire CV Therapeutics for $16 Per Share in Cash
CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350 - Dec 4 2008 4:19PM
CV Therapeutics Reports 2008 Third Quarter Financial Results
FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c
CV Therapeutics to Announce 2008 Third Quarter Financial Results on Thursday, November 6, 2008
CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2008
CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group
CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350 - Aug 27 2008 4:29PM
Journal of Cardiovascular Electrophysiology Publishes Data Showing Ranolazine Shortened QT Interval and Improved Cardiac Relaxation in Study of Patients With Long QT Syndrome
CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
CV Therapeutics Reports 2008 Second Quarter Financial Results
CVT Announces That FDA Continues to Review Ranexa(R) Applications
CV Therapeutics to Announce 2008 Second Quarter Financial Results on Thursday, July 31, 2008
CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina
Commercial Launch of Lexiscan(TM) (Regadenoson) Injection Triggers $10 Million Milestone Payment from TPG-Axon Capital to CV Therapeutics
Astellas Launches Lexiscan(TM) (Regadenoson) Injection for Use as a Pharmacologic Stress Agent in Radionuclide Myocardial Perfusion Imaging (MPI)
CV Therapeutics Announces Archives of Internal Medicine Publication of Study Showing 20 Percent of Heart Attack Patients in Premier Registry Experienced Angina at One Year
CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350 - Jun 1 2008 5:50AM
CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350 - May 28 2008 5:48PM
CV Therapeutics Announces Presentations at the American Diabetes Association 68th Scientific Sessions
CV Therapeutics Reports 2008 First Quarter Financial Results
European Medicines Agency Adopts Positive Opinion for Ranolazine for Treatment of Chronic Angina
BellwetherReport.com Initiates Analyst Coverage on ONNN, CVTX, EWBC and WFC
Market Pulse Breaking News Alert for Wednesday, April 16, 2008: NIHK -- Nighthawk Systems Announces Record Quarterly and Annual Revenue and Expects Significant Revenue From Its Set-Top Box Product Line!
CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection
CV Therapeutics to Announce 2008 First Quarter Financial Results on Friday, April 25, 2008
CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(TM) (regadenoson) Injection
CV Therapeutics' Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina